The Lisbon accelerator began by exporting ambitious founders to Boston. Fifteen years later, it is putting science through a tougher test: will it survive contact with farms, cities, customers and capital?
The luxury retailer’s venture builder pairs founders with grants, working retail channels and people who can say yes. Its real test comes when the pilot ends.
Electric tractors, diagnostic tools and space startups need more than a pitch deck. MOA Ventures puts industrial partners, investment and hands-on development around the science.
Behind Xiboba’s sweet drinks is an Indonesian investment company selling a more demanding proposition: a food business other people can run. MBV’s history shows how much depends on the menu, the delivery bill and the partner down the street.
The Barcelona venture builder recruits founders for business ideas tested abroad. Its bigger bet is that schools, headhunters and shared services can make the hard parts of starting up a little less lonely.
The Bellevue studio sells no tidy accelerator syllabus. It offers a pipeline, a workshop and flexible capital - the unglamorous machinery between a promising software idea and a company that can stand up on its own.
Suncoast Venture Studio is trying to make Sarasota more than a pleasant place to retire or relocate. Its wager is practical: build the startups first, recruit operators around validated ideas, and let a regional technology economy form company by company.
The New York studio has launched more than 60 healthcare companies since 2018 by treating the messy work of starting one - ideas, diligence, hiring, capital - as a system you can run again and again.
Shifamed is a Silicon Valley medical technology incubator founded in 2009 by serial entrepreneur Amr Salahieh. It combines human-centered design, in-house engineering, and R&D facilities to build medical device companies from concept to commercial launch, spinning out and incubating startups across cardiovascular, electrophysiology, and ophthalmology. Its portfolio and legacy companies have raised over $800M and produced multiple acquisitions by Boston Scientific, Abbott, Covidien, and Johnson & Johnson.